IRLA — IRulya Therapeutics Share News
0.000.00%
Last trade - 00:00- $355.93m
- $383.76m
Advisory: Alert incorrectly tagged to Quince Therapeutics withdrawn
Brief: Quince Therapeutics - On Feb 9, Engaged Lifesci Capital For Strategic Alternatives - SEC Filing
NASDAQ RESUMED AT 04:00 PM
Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:44 PM
NASDAQ RESUMED AT 03:41 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:06 PM
Brief: Quince Marks Final Patient Visit in NEAT Phase 3 Study
Quince Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Quince Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Quince Therapeutics Completes Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia
Brief: Quince Therapeutics To Participate At A-T Society's 2025 A-T Clinical Research Conference
Brief: Quince Therapeutics announces closing of up to $22 million private placement of securities
Brief: Quince Therapeutics Announces Pricing Of Up To $22 Mln Private Placement Of Securities
Brief: Quince Therapeutics Exceeds 75% Enrollment In Pivotal Phase 3 NEAT Clinical Trial In Ataxia-Telangiectasia
Quince Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Quince Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Quince Therapeutics Files For Common Stock Offering Of Up To $21.9 Million - SEC Filing
Brief: Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026